Thompson Siegel & Walmsley LLC Has $524,000 Position in Zoetis Inc. (ZTS)

Thompson Siegel & Walmsley LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 30.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,402 shares of the company’s stock after selling 3,700 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Zoetis were worth $524,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America raised its position in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares during the period. Assetmark Inc. raised its position in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after purchasing an additional 85 shares during the period. Point72 Asia Hong Kong Ltd purchased a new position in Zoetis in the first quarter valued at about $111,000. Advisory Services Network LLC purchased a new position in Zoetis in the first quarter valued at about $112,000. Finally, Peddock Capital Advisors LLC purchased a new position in Zoetis in the second quarter valued at about $140,000. 93.20% of the stock is currently owned by institutional investors.

Zoetis Inc. (NYSE:ZTS) opened at 64.16 on Friday. The firm has a market capitalization of $31.38 billion, a P/E ratio of 36.27 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $65.83. The company has a 50-day moving average price of $62.44 and a 200-day moving average price of $59.64.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.49 earnings per share. On average, equities research analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.

WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/thompson-siegel-walmsley-llc-sells-3700-shares-of-zoetis-inc-zts/1604480.html.

ZTS has been the topic of several research reports. BidaskClub raised Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Deutsche Bank AG reissued a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research report on Wednesday, September 6th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research report on Friday, September 1st. Finally, Argus reissued a “buy” rating and issued a $69.00 price objective (up from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $65.44.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.